- Home
- GDYN vs ARQT Comparison
GDYN vs ARQT Comparison
Compare GDYN & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GDYN | ARQT |
|---|---|---|
| Founded | 2006 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 603.0M | 3.3B |
| IPO Year | 2018 | 2020 |
Fundamental Metrics
Financial Performance| Metric | GDYN | ARQT |
|---|---|---|
| Price | $6.31 | $22.67 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 7 |
| Target Price | $10.67 | ★ $31.86 |
| AVG Volume (30 Days) | ★ 1.8M | 1.2M |
| Earning Date | 06-08-2026 | 05-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 120.00 | 88.79 |
| EPS | ★ 0.11 | N/A |
| Revenue | $111,283,000.00 | ★ $376,072,000.00 |
| Revenue This Year | $11.73 | $34.46 |
| Revenue Next Year | $14.11 | $29.77 |
| P/E Ratio | $58.55 | ★ N/A |
| Revenue Growth | N/A | ★ 91.34 |
| 52 Week Low | $6.00 | $11.86 |
| 52 Week High | $17.46 | $31.77 |
Technical Indicators
Market Signals| Indicator | GDYN | ARQT |
|---|---|---|
| Relative Strength Index (RSI) | 40.34 | 35.75 |
| Support Level | $6.16 | $22.56 |
| Resistance Level | $7.38 | $27.26 |
| Average True Range (ATR) | 0.41 | 1.26 |
| MACD | 0.03 | -0.26 |
| Stochastic Oscillator | 21.10 | 3.25 |
Price Performance
Historical ComparisonAbout GDYN Grid Dynamics Holdings Inc.
Grid Dynamics Holdings Inc is a provider of technology consulting, platform and product engineering, and advanced analytics services. The company delivers tailored solutions in several industry verticals like Tech, Media and Telecom, Retail, Finance and Consumer Packaged goods (CPG)/manufacturing. The company derives maximum revenue from Retails. Geographically company earns revenue from North America, Europe and other regions.
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.